were surging on unusually heavy volume Thursday, climbing $1.70, or 59%, to $4.55 in recent trading.
The small-cap biopharmaceutical announced results of a study that shows the use of BiovaxID, with or without concomitant Rituxan, can bring about long-lasting remissions in patients whose follicular non-Hodgkins lymphoma had initially relapsed after chemotherapy. The results of the study were published in the Sept. 20 issue of the
Journal of the National Cancer Institute
. (Rituxan is a drug marketed by
( DNA) and
The study by Dr. Susana Inoges and colleagues at the University of Navarra in Pamplona, Spain, found that these second remissions lasted longer than the patients' first remissions. In the study, 80% of the 25 patients achieved an immune response to the Biovaxid formulation, and among these responders, the median time of complete tumor remission has not been reached after nearly three years of follow-up.